Phospho-CDK6 (Tyr13) Antibody

What are the optimal experimental conditions for using Phospho-CDK6 (Tyr13) Antibody in different applications?

The optimal experimental conditions for Phospho-CDK6 (Tyr13) Antibody vary depending on the specific application. Based on extensive research data and manufacturer recommendations, the following protocols yield optimal results:

Western Blotting (WB):

• Recommended dilution: 1:500-1:1000

• Sample preparation: Total protein extracts from cells/tissues

• Controls: Include untreated samples and phosphatase-treated samples

• Detection systems: Both chemiluminescence and fluorescence-based systems are compatible

Western blot analysis confirms specificity, as demonstrated in experiments with 293 cells untreated or treated with hydroxyurea (HU), and HUVEC cells treated with calf intestinal phosphatase (CIP) .

Immunohistochemistry (IHC):

• Recommended dilution: 1:50-1:100

• Sample preparation: Paraffin-embedded tissue sections

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Controls: Include blocking peptide controls to confirm specificity

IHC analysis of paraffin-embedded human breast carcinoma tissue confirms specific staining that can be blocked with the cognate peptide .

Immunofluorescence (IF):

• Recommended dilution: 1:100-1:200

• Sample preparation: Methanol-fixed cells preferred

• Controls: Include secondary antibody-only controls and blocking peptide controls

Immunofluorescence staining of methanol-fixed HeLa cells shows discrete cellular localization patterns .

ELISA:

• Recommended dilution: Follow specific protocol optimization

• Sample preparation: Purified proteins or cell lysates

• Controls: Include phosphorylated and non-phosphorylated peptides as controls

How does CDK6 phosphorylation at Tyr13 influence T cell activation and immunotherapy outcomes?

Recent research has revealed a critical role for CDK6 phosphorylation in regulating T cell activity and immunotherapy responses. CDK6, particularly when phosphorylated, influences T cell function through several mechanisms:

T Cell Activation Pathway:
CDK6 phosphorylation affects T cell activation by modulating the CDK6-PTP-CD3ζ axis. When CDK6 is active, it phosphorylates and increases the activities of protein tyrosine phosphatases (PTPs), specifically PTP1B and T cell protein tyrosine phosphatase (TCPTP) . These activated phosphatases then:

• Decrease tyrosine phosphorylation of CD3ζ in the immunoreceptor tyrosine-based activation motifs (ITAMs)

• Reduce signal transduction required for T cell activation

• Ultimately diminish T cell activity and cytotoxic function

Immunotherapy Resistance:
High CDK6 expression positively correlates with immunotherapy resistance in 6 of 7 single-agent immunotherapy clinical studies for melanoma patients . This resistance occurs through CDK6's ability to attenuate T cell-mediated immune responses via the PTP pathway.

Experimental Evidence:

• In CDK6 knockout mice, frequencies of central memory T (Tcm) cells and effector memory T (Tem) cells were significantly increased in tumors

• Expression levels of IFN-γ, granzyme B, and TNF-α in CD8+ T cells were significantly elevated in CDK6 knockout mice compared to wild-type

• Targeting PTP1B and TCPTP enhances T cell activities and significantly improves the efficacy of adoptive T cell therapy, potentially offering superior results compared to directly targeting CDK6

This mechanistic understanding suggests that monitoring CDK6 phosphorylation status using Phospho-CDK6 (Tyr13) Antibody could help predict immunotherapy responses and identify patients who might benefit from combined CDK6 inhibition and immunotherapy approaches.

What methods can be used to validate the specificity of Phospho-CDK6 (Tyr13) Antibody in experimental systems?

Validating antibody specificity is critical for ensuring reliable experimental results. For Phospho-CDK6 (Tyr13) Antibody, several complementary approaches are recommended:

Phosphatase Treatment:
One of the most definitive validation methods is phosphatase treatment of samples:

• Treat cell/tissue lysates with calf intestinal phosphatase (CIP)

• Compare antibody reactivity between treated and untreated samples

• Loss of signal in phosphatase-treated samples confirms phospho-specificity

Blocking Peptide Competition:

• Pre-incubate the antibody with the phosphorylated peptide immunogen

• Apply the antibody-peptide mixture to your samples in parallel with antibody alone

• Specific signal should be significantly reduced or eliminated in the blocked sample

• Some suppliers offer blocking peptides specifically designed for these validation experiments

Genetic Approaches:

• Use CDK6 knockout cell lines or tissues as negative controls

• Compare wild-type vs. CDK6 knockout samples

• Absence of signal in knockout samples confirms specificity for CDK6 protein

Stimulus-Dependent Phosphorylation:

• Treat cells with agents known to alter CDK6 phosphorylation status

• For example, hydroxyurea (HU) treatment has been shown to affect CDK6 phosphorylation

• Monitor changes in signal intensity that correlate with expected phosphorylation changes

Cross-Validation with Other Antibodies:

• Use multiple antibodies targeting different epitopes of CDK6

• Compare phospho-specific vs. total CDK6 antibody staining patterns

The optimal validation approach involves combining multiple methods. For example, western blot analysis of extracts from 293 cells untreated or treated with HU, and HUVEC cells treated with CIP, provides strong evidence for the specificity of the Phospho-CDK6 (Tyr13) Antibody .

How does phosphorylation at Tyr13 affect CDK6's role in cell cycle regulation compared to other post-translational modifications?

CDK6 undergoes multiple post-translational modifications that differentially regulate its activity and function. Phosphorylation at Tyr13 represents a distinct regulatory mechanism with specific functional consequences:

Tyr13 Phosphorylation vs. Other Modifications:

Unique Aspects of Tyr13 Phosphorylation:
Phosphorylation at Tyr13 appears to be particularly important in specific cellular contexts. While Thr177 phosphorylation and Tyr24 dephosphorylation are known to promote kinase activity , the role of Tyr13 phosphorylation is more complex and context-dependent.

Functional Implications:

• CDK6 is probably involved in the control of the cell cycle and interacts with D-type G1 cyclins

• Specific phosphorylation at Tyr13 may create unique binding interfaces for CDK6 interaction partners

• In immune cells, CDK6 phosphorylation affects protein tyrosine phosphatase activity, influencing T cell receptor signaling

Tissue-Specific Relevance:
CDK6 is expressed ubiquitously but accumulates in specific tissues, including squamous cell carcinomas, proliferating hematopoietic progenitor cells, beta-cells of pancreatic islets of Langerhans, and neuroblastomas, with reduced levels in differentiating cells . The relative importance of Tyr13 phosphorylation may vary across these tissue contexts.

Understanding these distinctions is crucial for researchers designing experiments to investigate specific aspects of CDK6 regulation and function in different cellular contexts.

What are the technical considerations for optimizing Western blot detection of phosphorylated CDK6?

Detecting phosphorylated proteins by Western blot requires careful optimization to maintain phosphorylation status and achieve specific detection. For Phospho-CDK6 (Tyr13), the following technical considerations are critical:

Sample Preparation:

• Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in lysis buffers

• Use cold buffers and keep samples on ice to minimize phosphatase activity

• Process samples quickly to prevent dephosphorylation

• Consider using specialized phosphoprotein extraction buffers

Gel Electrophoresis and Transfer:

• Use freshly prepared running and transfer buffers

• Consider using Phos-tag™ acrylamide gels for enhanced separation of phosphorylated proteins

• Optimize transfer conditions for high molecular weight proteins (CDK6 has a predicted MW of 36kDa)

Blocking and Antibody Incubation:

• Use 5% BSA in TBST rather than milk for blocking (milk contains phosphatases)

• Dilute Phospho-CDK6 (Tyr13) Antibody 1:500-1:1000 in 5% BSA-TBST

• Incubate with primary antibody overnight at 4°C for optimal binding

• Wash thoroughly with TBST to reduce background

Detection and Controls:

• Include positive controls (e.g., lysates from cells with known CDK6 phosphorylation)

• Include negative controls (e.g., phosphatase-treated samples)

• Consider using fluorescence-based detection systems for better quantification

• For chemiluminescence, avoid overexposure which can mask phosphorylation-specific signals

Validation Strategies:

• Perform parallel blots with total CDK6 antibody to normalize phospho-signals

• Use blocking peptide competition as a specificity control

• Compare results across different cell types or treatment conditions

Western blot analysis of extracts from 293 cells untreated or treated with hydroxyurea (HU) demonstrates the ability of the antibody to detect changes in phosphorylation status under different cellular conditions . Similarly, treatment with calf intestinal phosphatase (CIP) can serve as a negative control, as it should eliminate the phospho-specific signal .

How can researchers distinguish between CDK6 phosphorylated at Tyr13 and other phosphorylation sites?

Distinguishing between different phosphorylation sites on the same protein requires careful experimental design and multiple complementary approaches:

Phospho-Specific Antibodies:

• Use highly specific antibodies that detect only CDK6 phosphorylated at Tyr13

• The Phospho-CDK6 (Tyr13) Antibody is generated using the peptide sequence Q-Q-Y(p)-E-C derived from Human CDK6

• Antibodies are purified by affinity-chromatography using epitope-specific phosphopeptide, and non-phospho specific antibodies are removed by chromatography using non-phosphopeptide

Site-Directed Mutagenesis:

• Generate CDK6 mutants where Tyr13 is replaced with phenylalanine (Y13F)

• Compare wild-type and mutant CDK6 phosphorylation patterns

• Y13F mutants should not be recognized by the Phospho-CDK6 (Tyr13) Antibody

Mass Spectrometry-Based Approaches:

• Perform tandem mass tag mass spectrometry (TMT-MS) analysis

• This approach can identify and quantify multiple phosphorylation sites simultaneously

• Similar to the approach used in research to identify S/TP site phosphorylation of PTPs

Phosphatase Treatment Combined with Site-Specific Detection:

• Treat samples with phosphatases that have different site specificities

• Monitor changes in detection by Phospho-CDK6 (Tyr13) Antibody

• Compare with detection by antibodies targeting other phosphorylation sites

In Vitro Kinase Assays:

• Perform in vitro kinase assays with purified kinases known to phosphorylate specific sites

• Analyze resulting phosphorylation patterns with phospho-specific antibodies

• This approach can help identify the kinases responsible for Tyr13 phosphorylation

Using a combination of these approaches provides robust evidence for site-specific phosphorylation. The specificity of the Phospho-CDK6 (Tyr13) Antibody has been validated in multiple studies, confirming that it detects endogenous levels of CDK6 only when phosphorylated at tyrosine 13 .

What is the relationship between CDK6 phosphorylation and protein tyrosine phosphatase activity in immune cell function?

Recent research has uncovered a crucial relationship between CDK6 phosphorylation and protein tyrosine phosphatase (PTP) activity in immune cell function, particularly in T cell activation pathways:

Mechanistic Pathway:

• CDK6, when active, directly phosphorylates and activates protein tyrosine phosphatases, specifically PTP1B and T cell protein tyrosine phosphatase (TCPTP)

• These activated phosphatases then dephosphorylate CD3ζ in immunoreceptor tyrosine-based activation motifs (ITAMs)

• Reduced CD3ζ phosphorylation decreases T cell receptor signaling

• This ultimately diminishes T cell activation and cytotoxic function

Experimental Evidence:

• TMT-MS analysis showed that CDK6 inhibition leads to decreased serine/threonine phosphorylation but increased tyrosine phosphorylation of 105 proteins

• Gene Ontology enrichment analysis revealed that "T cell receptor signaling pathway" was the top-ranked annotation group among increased tyrosine-phosphorylated proteins

• Several PTPs displayed decreased phosphorylation at CDK-dependent S/TP sites upon treatment with palbociclib (a CDK4/6 inhibitor)

• In vitro kinase assays demonstrated that PTP1B and TCPTP are specifically phosphorylated by cyclin D3/CDK6

• The phosphatase activities of PTP1B and TCPTP were significantly enhanced when they were phosphorylated by CDK6 in vitro

Functional Consequences:

• CDK6 depletion in the tumor microenvironment inhibits tumor growth

• CDK6 knockout mice show increased frequencies of central memory T (Tcm) cells and effector memory T (Tem) cells in tumors

• Expression levels of IFN-γ, granzyme B, and TNF-α in CD8+ T cells are significantly increased in CDK6 knockout compared with wild-type mice

Therapeutic Implications:

• Targeting PTP1B and TCPTP enhances T cell activities and significantly improves the efficacy of adoptive T cell therapy

• This approach may be superior to directly targeting CDK6 for enhancing immunotherapy responses

• High CDK6 expression positively correlates with immunotherapy resistance in 6 of 7 single-agent immunotherapy clinical studies for melanoma patients

This emerging understanding highlights the importance of studying CDK6 phosphorylation status in immune contexts and suggests new therapeutic strategies for enhancing immunotherapy efficacy.

What sample preparation techniques maximize detection of phosphorylated CDK6 in different tissue types?

Detecting phosphorylated proteins requires specialized sample preparation techniques to preserve phosphorylation status. For Phospho-CDK6 (Tyr13) in different tissue types, consider the following optimized protocols:

Cell Culture Samples:

• Harvest cells quickly to minimize phosphatase activity

• Wash cells in ice-cold PBS containing phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4)

• Lyse cells in buffer containing:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • 0.5% sodium deoxycholate

  • Phosphatase inhibitor cocktail

  • Protease inhibitor cocktail

• Maintain samples at 4°C throughout processing

Tissue Samples:

• Flash-freeze tissue samples immediately after collection

• Pulverize frozen tissue under liquid nitrogen

• Homogenize in cold lysis buffer containing phosphatase inhibitors

• Centrifuge at high speed (14,000 x g) at 4°C to remove debris

• For tissues with high phosphatase activity (e.g., brain, liver), consider using higher concentrations of phosphatase inhibitors

For Western Blotting:

• Load 20-50 μg of total protein per lane

• Include positive controls (e.g., cells treated with tyrosine phosphatase inhibitors)

• Include phosphatase-treated samples as negative controls

For Immunohistochemistry:

• Fix tissues in 10% neutral buffered formalin for no more than 24 hours

• For better phospho-epitope preservation, consider alternative fixatives such as zinc-based fixatives

• Perform heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Block endogenous phosphatases before antibody incubation

For Immunofluorescence:

• Methanol fixation is preferred for CDK6 phospho-epitope preservation

• Avoid prolonged permeabilization which can extract phosphoproteins

• Include phosphatase inhibitors in all buffers

Tissue-Specific Considerations:
CDK6 is expressed ubiquitously but accumulates in specific tissues:

• Squamous cell carcinomas

• Proliferating hematopoietic progenitor cells

• Beta-cells of pancreatic islets of Langerhans

• Neuroblastomas

Each of these tissue types may require specific modifications to standard protocols to optimize phospho-CDK6 detection.

How do experimental treatments affect the phosphorylation status of CDK6 at Tyr13?

Various experimental treatments can modulate the phosphorylation status of CDK6 at Tyr13, providing valuable tools for studying CDK6 regulation and function:

Phosphatase Treatments:

• Calf Intestinal Phosphatase (CIP): Treatment of cell extracts with CIP results in loss of Phospho-CDK6 (Tyr13) antibody reactivity, confirming the phospho-specificity of the antibody

• This approach provides a negative control for validating antibody specificity

Cell Cycle Modulators:

• Hydroxyurea (HU): Treatment of 293 cells with HU alters CDK6 phosphorylation status at Tyr13, as demonstrated in western blot analyses

• Serum starvation and release: Synchronization of cells by serum starvation followed by release into serum-containing medium can reveal cell cycle-dependent changes in CDK6 phosphorylation

Kinase Inhibitors:

• CDK4/6 Inhibitors: Palbociclib treatment affects CDK6-dependent phosphorylation pathways, though its direct effect on Tyr13 phosphorylation requires further investigation

• Tyrosine Kinase Inhibitors: May indirectly affect CDK6 Tyr13 phosphorylation by modulating upstream kinase activity

CDK6 Degraders:

• Selective CDK6 degraders such as BSJ-03-0123 can be used to study the consequences of CDK6 depletion on downstream signaling pathways

• This approach allows comparison between inhibition of kinase activity versus protein depletion

Genetic Approaches:

• CDK6 Knockout: Complete absence of CDK6 protein in knockout models provides a definitive negative control

• Site-directed mutagenesis: Y13F mutants prevent phosphorylation at this specific site

T Cell Activation Models:

• T Cell Receptor (TCR) Stimulation: Activation of T cells through the TCR can modulate CDK6 phosphorylation

• Cytokine Treatment: Various cytokines may affect CDK6 phosphorylation status in immune cells

The combination of these approaches allows researchers to dissect the regulation and function of CDK6 phosphorylation at Tyr13 in different cellular contexts. For example, western blot analysis of extracts from 293 cells untreated or treated with HU demonstrates the ability of the antibody to detect changes in phosphorylation status under different cellular conditions .

What are the latest research findings on targeting the CDK6 phosphorylation pathway in cancer immunotherapy?

Recent research has revealed compelling evidence for targeting the CDK6 phosphorylation pathway to enhance cancer immunotherapy effectiveness:

CDK6 and Immunotherapy Resistance:

• High CDK6 expression positively correlates with immunotherapy resistance in 6 of 7 single-agent immunotherapy clinical studies for melanoma patients

• This correlation suggests CDK6 as a potential biomarker for predicting immunotherapy response

Mechanistic Understanding:

• CDK6, but not CDK4, cyclin D1, or D2, in the tumor microenvironment (TME) plays a critical role in tumor growth

• CDK6 functions by directly phosphorylating and activating protein tyrosine phosphatases (PTPs), specifically PTP1B and T cell protein tyrosine phosphatase (TCPTP)

• These activated phosphatases decrease CD3ζ tyrosine phosphorylation in immunoreceptor tyrosine-based activation motifs (ITAMs)

• Reduced CD3ζ phosphorylation consequently diminishes T cell activation and function

Experimental Evidence:

• In CDK6 knockout mice:

  • Frequencies of central memory T (Tcm) cells and effector memory T (Tem) cells were significantly increased in tumors

  • Expression levels of IFN-γ, granzyme B, and TNF-α in CD8+ T cells were significantly elevated

  • These changes indicate enhanced T cell activation and cytotoxic function

Novel Therapeutic Approaches:

• Targeting PTP1B and TCPTP has shown promising results for enhancing T cell activities

• This approach significantly improves the efficacy of adoptive T cell therapy

• Importantly, targeting PTPs appears to be superior to directly targeting CDK6 for enhancing immunotherapy responses

Experimental Models:

• Tandem mass tag mass spectrometry (TMT-MS)-based comparative analysis has identified key proteins in the CDK6-PTP-CD3ζ signaling axis

• In vitro kinase assays have confirmed that PTP1B and TCPTP are specifically phosphorylated by cyclin D3/CDK6, but not other cyclin D/CDK combinations